2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

Snap’s flagship product is the smartphone app Snapchat, which allows its users to communicate via ephemeral short videos and ...

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

Amgen’s third-quarter product sales grew 24% (or 8% excluding ... Management raised its top-line guidance for 2024 by $100 million at the midpoint to $33 billion-$33.8 billion and narrowed ...

Amgen AMGN reported third ... Total revenues of $8.51 billion came in line with the Zacks Consensus Estimate. Total revenues rose 23% year over year. Total product revenues increased 24% from ...

Total product revenues increased ... interested in the progress of Amgen’s GLP-1 receptor candidate, MariTide (maridebart cafraglutide), for obesity. Top-line 52-week data from the phase II ...

While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...

My name is Julianne, and I will be your conference facilitator today for Amgen's third quarter 2024 financial results ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.